SL1009 (sodium dichloroacetate)

Name: SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Genotype-specific metabolic management
Published: 2026-09-14T15:39:06-04:00

Pyruvate dehydrogenase complex deficiency

Manufacturer: Saol Therapeutics
Regulatory submission: NDA resubmitted June 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Genotype-specific metabolic management

1 evidence topic · 1 source

DLD-related disease: dietary and acute metabolic management

“Branched-chain amino acid restriction” (opens the source at this quote in a new tab)
“Dextrose-containing IV fluids” (opens the source at this quote in a new tab)